Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Teva Pharmaceutical Industries Ltd. (TEVA) presented new efficacy and safety findings for its investigational D1 antagonist ecopipam in pediatric Tourette Syndrome at the MDS Congress. The data included post hoc analyses and interim long-term open-label extension findings.
Teva Pharmaceuticals announced new efficacy and safety data for ecopipam, an investigational treatment targeting pediatric patients with Tourette Syndrome. Ecopipam is a first-in-class selective D1 dopamine receptor antagonist.